Sort
48,018 grants matching “immunotherapy”
Fast Targeted Spectroscopic Imaging for Brain Tumor Imaging at 3T and 7T
$543,959Hoby P Hetherington · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · EB
Impact of Foreign Bodies on Infection Susceptibility, Disease and Mucosal Remodeling of the Urinary Tract
$543,778Scott J Hultgren · Washington University · R01 · FY2023 · DK
HIGH-THROUGHPUT TCR REPERTOIRE-BASED PLATFORMS FOR ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPY
$543,765The General Hospital Corporation · · FY2018 · Defense Health Agency
CD4+ T Cells in Acute Versus Chronic HCV Infection
$543,750Georg Michael Lauer · Massachusetts General Hospital · R01 · FY2015 · AI
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$543,717Stephen H Safe · Texas A&M University · R01 · FY2024 · CA
Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells
$543,694Johannes Zakrzewski · Hackensack University Medical Center · R37 · FY2023 · CA
Focal segmental glomerulosclerosis: Treatment
$543,656Jeffrey Burnett Kopp · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2012 · DK
Focal segmental glomerulosclerosis: Treatment
$543,656Jeffrey Burnett Kopp · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK
Finding the optimal balance of immunotherapy efficacy and toxicity.
$543,590David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2024 · AI
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
$543,566Michail Sitkovsky · Northeastern University · R01 · FY2009 · CA
Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer
$543,560Dan R Littman · New York University School Of Medicine · R01 · FY2024 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$543,527James R. Heath · Institute For Systems Biology · U01 · FY2017 · CA
Immune epigenetic biomarkers of survival in glioma epidemiology
$543,240John K. Wiencke · University Of California, San Francisco · R01 · FY2021 · CA
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment
$543,192Peixuan Guo · Ohio State University · U01 · FY2019 · CA
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma
$543,162David M Koelle · University Of Washington · P01 · FY2020 · CA
Development of a Therapeutic for Brain Tumor Immunotherapy
$543,119John H Sampson · Duke University · R01 · FY2018 · CA
Engineered Nanoformulation for Immune-modulation in Cancer
$543,107Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2023 · CA
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS
$543,088David Reardon · Duke University · P50 · FY2010 · NS
3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation
$543,064Joseph F Costello · University Of California, San Francisco · R01 · FY2024 · CA
Non-coding RNA regulation of Myeloid Cells
$543,051Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2025 · CA
Immune Therapy for Brain Metastasis
$542,905Lucia Beatrice Jilaveanu · Yale University · R01 · FY2024 · CA
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy
$542,889Jun Wang · New York University School Of Medicine · R37 · FY2024 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
$542,873Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2024 · CA
A HER-2/neu pulsed DC1 vaccine for patients with DCIS
$542,825Brian Joseph Czerniecki · University Of Pennsylvania · R01 · FY2010 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$542,768Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2017 · CA